Cell labelling for in vivo use and in process quality control

点击翻译按钮获取中文摘要

The consortium of Altrika, the University of Edinburgh’s School of Chemistry, Roslin Cellab and Barts and The London bring R&D, manufacturing, clinical and commercialisation experience to the challenge of tracking clinically relevant cell populations in vitro and in vivo. The absence of an in vivo tracking methodology leads to R&D, manufacturing and clinical constraints, valuable researcher time and cell yield losses, and associated costs. This project utilises an innovative, non-toxic cell label that is stable, cost-effective and easy to detect. It will demonstrate applicability to a range of regenerative medicine therapies for unmet clinical needs, as well as increasing the efficiency of R&D activities and manufacturing processes, and improving the efficacy of clinical delivery. Given the growth of regenerative medicine, this platform could reduce industry costs by as much as $275m in 2020.